$NVAX (-0,36 %) | Novavax Q3 '24 Earnings Highlights:

🔹 Revenue: $84.5M (Est. $61.3M) 🟢

🔹 Loss per Share: -$0.76 (Est. -$0.77) 🟢

🔹 R&D Expenses: $87.2M (Est. $104.1M) 🟢

🔹 Cash and Cash Equivalents: $573.6M (Est. $530.7M) 🟢

🔹 Product Sales: $38.2M (Est. $69.8M) 🔴

FY24 Guidance: 

🔹 Total Revenue: $650M - $700M (Prior: $700M - $800M) 🔴

🔹 Product Sales: $175M - $225M (Prior: $275M - $375M) 🔴

🔹 Licensing & Royalties: $475M (up from prior $425M) 🟢

Key Highlights: 

🔸 FDA lifted clinical hold on COVID-19-Influenza Combination vaccine, enabling Phase 3 trials. 

🔸 Achieved authorization for updated 2024-2025 COVID-19 vaccine for ages 12+ in the U.S. and EU. 

🔸 Partnership with Sanofi on track, with commercial responsibilities for Nuvaxovid to transfer in 2025.

Financial Overview: 

🔸 Net Loss: $121M (DOWN from $131M YoY)

🔸 Significant cost reductions in R&D and SG&A, down 26% YoY in Q3.

CEO Commentary: 

🔸 "Focused on strategic growth beyond COVID-19, leveraging partnerships like Sanofi and expanding our proven technology platform."